These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 28332240

  • 1. Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
    Higashi Y.
    Int J Urol; 2017 Jun; 24(6):412-424. PubMed ID: 28332240
    [Abstract] [Full Text] [Related]

  • 2. [Lower urinary tract symptoms related to benign prostatic hyperplasia and erectile dysfunction: A systematic review].
    Peyronnet B, Seisen T, Phé V, Misrai V, de la Taille A, Rouprêt M.
    Presse Med; 2017 Mar; 46(2 Pt 1):145-153. PubMed ID: 27745762
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endothelial dysfunction and vascular disease - a 30th anniversary update.
    Vanhoutte PM, Shimokawa H, Feletou M, Tang EH.
    Acta Physiol (Oxf); 2017 Jan; 219(1):22-96. PubMed ID: 26706498
    [Abstract] [Full Text] [Related]

  • 9. Cyclic guanosine monophosphate-enhancing reduces androgenic extracellular regulated protein kinases-phosphorylation/Rho kinase II-activation in benign prostate hyperplasia.
    Liu CM, Fan YC, Lo YC, Wu BN, Yeh JL, Chen IJ.
    Int J Urol; 2014 Jan; 21(1):87-92. PubMed ID: 23692571
    [Abstract] [Full Text] [Related]

  • 10. Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation.
    Zenzmaier C, Kern J, Sampson N, Heitz M, Plas E, Untergasser G, Berger P.
    Endocrinology; 2012 Nov; 153(11):5546-55. PubMed ID: 22948216
    [Abstract] [Full Text] [Related]

  • 11. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC.
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [Abstract] [Full Text] [Related]

  • 12. Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure.
    Katz SD.
    Congest Heart Fail; 2003 Apr; 9(1):9-15. PubMed ID: 12556672
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?
    Shimizu S, Tsounapi P, Shimizu T, Honda M, Inoue K, Dimitriadis F, Saito M.
    Int J Urol; 2014 Sep; 21(9):856-64. PubMed ID: 24930630
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress.
    Russo I, Del Mese P, Doronzo G, Mattiello L, Viretto M, Bosia A, Anfossi G, Trovati M.
    Endocrinology; 2008 Apr; 149(4):1480-9. PubMed ID: 18079207
    [Abstract] [Full Text] [Related]

  • 18. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease.
    Ivy DD, Kinsella JP, Ziegler JW, Abman SH.
    J Thorac Cardiovasc Surg; 1998 Apr; 115(4):875-82. PubMed ID: 9576224
    [Abstract] [Full Text] [Related]

  • 19. Testosterone Deficiency and Endothelial Dysfunction: Nitric Oxide, Asymmetric Dimethylarginine, and Endothelial Progenitor Cells.
    Hotta Y, Kataoka T, Kimura K.
    Sex Med Rev; 2019 Oct; 7(4):661-668. PubMed ID: 30987932
    [Abstract] [Full Text] [Related]

  • 20. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
    Schaffner D, Lazaro A, Deibert P, Hasselblatt P, Stoll P, Fauth L, Baumstark MW, Merfort I, Schmitt-Graeff A, Kreisel W.
    World J Gastroenterol; 2018 Oct 14; 24(38):4356-4368. PubMed ID: 30344420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.